Cadrenal Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2023 to Q2 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Cadrenal Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2023 to Q2 2025.
  • Cadrenal Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2025 was 35.1 %, a 152% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2025 35.1 +21.2 +152% Jun 30, 2025
Q1 2025 34.6 +24.4 +239% Mar 31, 2025
Q4 2024 29.8 +20.6 +222% Dec 31, 2024
Q3 2024 20.7 -53 -71.9% Sep 30, 2024
Q2 2024 14 Jun 30, 2024
Q1 2024 10.2 Mar 31, 2024
Q4 2023 9.26 Dec 31, 2023
Q3 2023 73.7 Sep 30, 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.